People with dark skin injected subdermally with CaHA do not show signs of keloid formation, hypertrophic scarring, or hyper- or hypopigmentation. Because of this safety feature, as well as other characteristics of the product already shown in clinical literature, CaHA is an attractive dermal filler in this population.
No takes yet. Share an insight, caveat, or question.
Marmur et al. (2009) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: